Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen Doubles Down On FOP With Blueprint Pact

Deal could be worth up to $535m

Executive Summary

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

You may also be interested in...



Blow To Ipsen As FerGene Nabs CEO Meek

The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.

Ipsen CBO: We Are Seeking Fresh Rare Disease Buys

Ipsen’s chief business officer tells Scrip that buying Canada’s Clementia Pharmaceuticals this year gave the French group’s rare disease operations an “anchor asset” to build on.

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel